Metabolomics combined with network pharmacology to explore the mechanisms of modified Guishen pill to ameliorate polycystic ovary syndrome. (September 2022)

• Record Type: Journal Article
• Authors: Tian, Jiayu; Xu, Yanqiu; Xiong, Yu; Zuo, Ling; Zhou, Min; Cao, Chunhao; Huang, Xuekuan; Wang, Jianwei
• Is Part Of: Computers in biology and medicine. Volume 148(2022)
• Publication Date: 2022-09
• Subjects: Polycystic ovary syndrome -- Modified guishen pill -- Metabolomics -- Network pharmacology; Medicine -- Data processing -- Periodicals; Biology -- Data processing -- Periodicals; 610.285
• DOI: 10.1016/j.compbiomed.2022.105790
• Languages: English
• ISSNs: 0010-4825

Abstract

Abstract: Background: The modified Guishen pill (MGP) has a prominent therapeutic effect on polycystic ovary syndrome (PCOS). However, its mechanism is still unclear. This study aimed to uncover the mechanism of MGP for PCOS treatment through a comprehensive strategy integrating metabolomics and network pharmacology. Methods: A letrozole-induced PCOS model was used to evaluate ovarian function in rats. Plasma metabolomics was used to authenticate differential metabolites and enriched related pathways using the MetaboAnalyst platform. Network pharmacology was utilized to explore the endogenous targets of MGP treatment for PCOS. Finally, the potential targets and related biological functions were verified experimentally. Results: MGP improved PCOS symptoms by regulating abnormal levels of sex hormones and alleviating ovarian pathological changes in rats; fifty-four potential differential metabolites involved in MGP treatment for PCOS, and the hub genes derived from network pharmacology were consistent with the metabolomic analysis results to varying degrees. The comprehensive analysis identified that a key novel target for endothelial nitric oxide synthase (eNOS/NOS3), five key metabolites (ornithine, citrulline, l -glutamic acid, acetylornithine, and hydroxyproline), and one pathway (arginine and proline metabolism) were related to the therapy of PCOS with MGP. Subsequently, we verified the localization and expression of eNOS in the ovaries, and it significantly improved insulin resistance, apoptosis, and oxidative stress in letrozole-induced PCOS rats. Conclusion: Our work reveals the complex mechanism of MGP therapy for PCOS. This study is a successful paradigm for elucidating the pharmacological mechanism of the traditional Chinese medicine compound. Highlights: Modified Guishen pill (MGP) is a novel discovery as an effective Chinese herbal compound for treating of PCOS. eNOS was identified as a novel key target for MGP treatment of PCOS through metabolomics combined with network pharmacology. MGP could significantly improve insulin resistance, and reduce apoptosis and oxidative stress in letrozole-induced PCOS rats by up-regulating the expression of eNOS. The comprehensive strategy integrating metabolomics and network pharmacology provides an optimal way to elucidate the pharmacological mechanism of Chinese herbal compound.